Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. - Powerful Science for Life
OvaDx® Ovarian Cancer Diagnostic Test
Arrayit Corporation and Avant Diagnostics, Inc. provide the market’s first large panel biomarker monitoring test for ovarian cancer (OVC). OvaDx® is advanced microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA approval, Avant will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1®, and transvaginal ultrasound.
Click here to read the article featuring Arrayit OvaDx® and Angelina Jolie.
Table of Contents
Arrayit Corporation and Avant Diagnostics, Inc. have developed a advanced monitoring test for ovarian cancer diagnostics.
The Arrayit Corporation and Avant Diagnostics, Inc. OvaDx® test is manufactured using the highest level of quality control (QC) and quality assurance (QA) available. Quality control and quality assurance of each manufactured test ensures that OvaDx® performance will meet or exceed the highest diagnostics standards.
OvaDx® is an advanced microarray-based diagnostic test that measures the activation of the immune system in response to ovarian tumor cell development. Patient sera are applied to OvaDx® microarrays to allow binding between proteomic biomarkers in the patient samples and capture agents on the microarrays. The microarrays are washed and scanned to produce a digital readout for each serum sample, and the data are quantified and analyzed in software to generate the test results. Clinicians will appreciate the following feaures of this product:
OvaDx® Blood Cards. Patient samples for OvaDx® diagnostic testing can be submitted using Arrayit Corporation blood cards. Place 5 large drops of fresh patient blood inside the red box of a new card. Arrayit’s unique competitive linear transfer chromotography technology partitions the whole blood components from left to right such that the serum containing the OvaDx® biomarkers separates cleanly from the red blood cells in 1 minute. Please allow the card to dry for 10 minutes prior to mailing. Dried cards should be placed in the airtight mailing envelopes supplied with the sampling kit and mailed to our Sunnyvale laboratories for testing.
Fresh blood (0.5-1.0 ml) should be drawn intravenously and collected in a red-top tube with no additive. Samples should be centrifuged immediately for 5 min at 6,000 rpm (2,000 x g) to isolate the serum fraction (top layer). The serum (0.1-0.25 ml) should be transferred to a fresh microfuge tube or sample vial and frozen immediately at -20°C or -70°C. Previously prepared samples stored at -20°C or -70°C are also acceptable. Blood samples can also be collected using blood cards provided by Avant Diagnostics, Inc. Samples should be labeled unambiguously with a permanent marker, adhesive label or by barcoding. Frozen Samples should be shipped overnight on dry ice with sample annotation and complete clinician contact information and blood cards should be shipped at room temperature:
927 Thompson Place
Sunnyvale, CA 94085
Telephone: (408) 744-1331
Avant Diagnostics, Inc. provides a full report for each patient sample including benchmarks for the following experimental parameters:
Please contact us if you have any comments, suggestions, or if you need technical assistance. We can be reached at all hours by electronic mail (email@example.com) or by telephone (408-744-1331) from Monday-Friday 8:00 AM-6 PM PST. Please remember that we want to hear about your successes!
VIP genotyping platforms
Biomarker discovery services
Microarray substrate slides
Amplification and labeling
Arrayit Corporation and Avant Diagnostics, Inc. OvaDx® Large Panel Ovarian Cancer Diagnostic Test has been developed for diagnostic purposes and will be sold for clinical applications upon FDA approval. Extreme care and exact attention should be practiced in the preparation and storage of OvaDx® patient samples and use of the diagnostic information obtained from the test. OvaDx® manufacturing and testing are subject to extensive quality control and are guaranteed to perform as described when used with properly prepared patient samples. Avant Diagnostic’s liability is limited to test replacement only, any misuse of this diagnostic product is the full responsibility of the clinician, and Avant Diagnostics makes no warranty or guarantee under such circumstances.
Copyright 1993-2019 Arrayit Corporation. All rights reserved.